Citations 3
Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)
Ζεκερίδου, Αναστασία , Gutman, Jonathan, Lowe, Mallory, Eggmann, Sadie, McKeon, Andrew, Pittock, Sean J., Yi, Jessica J., Newsome, Scott D., Chou, Justin, Blarcom, Tom Van, Han, Xue, Sun, John, Sengupta, Shouvonik , Tooker, Ryan, Mehta, Aditi, Grayson, Dena , Gehchan, N., Piquet, Amanda L. , Gergis, Usama , Gutman, Jonathan A. , Kenderian, Saad S. , McKeon, Andrew , Pittock, Sean J. , Rakočević, Goran , Dalakas, Marinos C.
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available
Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018)
Ζεκερίδου, Αναστασία , Nie, Esther H. , Chung, James , Piquet, Amanda L. , Borie, Dominic C. , Dalakas, Marinos C.
Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available
Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria
Chia, Nicholas , McKeon, Andrew , Dalakas, Marinos C. , Bower, James H., Klassen, Bryan T. , Dubey, Divyanshu , Zalewski, Nicholas L. , Duffy, Dustin, Pittock, Sean J. , Ζεκερίδου, Αναστασία , Pittock, S J , Chia, Nicholas H , Dubey, Divyanshu , Zekeridou, Anastasia , McKeon, Andrew , Flanagan, Eoin P. , Dubey, Divyanshu
Annals of Clinical and Translational Neurology | May 22, 2023 | Volume: 10 | Issue: 7 | Pages: 1083-1094
AbstractBackgroundStiff person spectrum disorder (SPSD) is heterogeneous, and accurate diagnosis can be challenging.MethodsPatients referred for diagnosis/suspicion of SPSD at the Mayo Autoimmune Neurology Clinic from July 01, 2016, to June 30, 2021, were retrospectively identified. SPSD diagnosis was defined as clinical SPSD manifestations confirmed by an autoimmune neurologist and seropositivity for high‐titer GAD65‐IgG (>20.0 nmol/L), glycine‐receptor‐IgG or amphiphysin‐IgG, and/or confirmatory electrodiagnostic studies (essential if seronegative). Clinical presentation, examination, and ancillary testing were compared to differentiate SPSD from non‐SPSD.ResultsOf 173 cases, 48 (28%) were diagnosed with SPSD and 125 (72%) with non‐SPSD. Most SPSD were seropositive (41/48: GAD65‐IgG 28/41, glycine‐receptor‐IgG 12/41, amphiphysin‐IgG 2/41). Pain syndromes or functional neurologic disorder were the most common non‐SPSD diagnoses (81/125, 65%). SPSD patients more commonly reported exaggerated startle (81% vs. 56%, p = 0.02), unexplained falls (76% vs. 46%, p = 0.001), and other associated autoimmunity (50% vs. 27%, p = 0.005). SPSD more often had hypertonia (60% vs. 24%, p < 0.001), hyperreflexia (71% vs. 43%, p = 0.001), and lumbar hyperlordosis (67% vs. 9%, p < 0.001) and less likely functional neurologic signs (6% vs. 33%, p = 0.001). SPSD patients more frequently had electrodiagnostic abnormalities (74% vs. 17%, p < 0.001), and at least moderate symptomatic improvement with benzodiazepines (51% vs. 16%, p < 0.001) or immunotherapy (45% vs. 13% p < 0.001). Only 4/78 non‐SPSD patients who received immunotherapy had alternative neurologic autoimmunity.InterpretationMisdiagnosis was threefold more common than confirmed SPSD. Functional or non‐neurologic disorders accounted for most misdiagnoses. Clinical and ancillary testing factors can reduce misdiagnosis and exposure to unnecessary treatments. SPSD diagnostic criteria are suggested.